3sbio (1530.HK) stock price, revenue, and financials
3sbio market cap is $15.8 b, and annual revenue was ¥6.38 b in FY 2021
$15.8 B
1530.HK Mkt cap, 07-Jun-2022¥6.4 B
3sbio Revenue FY, 20213sbio Gross profit (FY, 2021)5.7 B
3sbio Net income (FY, 2021)1.6 B
3sbio EBITDA (FY, 2021)2.2 B
3sbio EBIT (FY, 2021)1.8 B
3sbio Cash, 31-Dec-20212.9 B
3sbio EV15.6 B
3sbio Revenue Breakdown
3sbio revenue breakdown by business segment: 100.0% from PHARMACEUTICAL DIVERSIFIED
3sbio Income Statement
Annual
| CNY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Revenue | 4.6b | 5.3b | 5.6b | 6.4b |
Cost of goods sold | (564.0m) | (591.4m) | (702.0m) | (777.3m) |
Gross profit | 4.1b | 4.8b | 5.0b | 5.7b |
R&D expense | (362.7m) | (526.6m) | (590.3m) | (753.9m) |
Operating expense total | (2.4b) | (3.2b) | (3.2b) | (3.5b) |
Depreciation and amortization | (313.3m) | (334.0m) | (538.7m) | (329.0m) |
EBITDA | 1.7b | 1.6b | 1.8b | 2.2b |
EBIT | 1.3b | 1.2b | 1.2b | 1.8b |
Interest expense | (138.4m) | (109.5m) | (81.1m) | (66.5m) |
Interest income | 64.8m | 83.9m | 84.5m | 98.7m |
Pre tax profit | 1.5b | 1.2b | 979.1m | 1.9b |
Income tax expense | (218.3m) | (242.8m) | (208.0m) | (241.2m) |
Net Income | 1.3b | 980.2m | 771.1m | 1.6b |
Half Year
| CNY | H1, 2019 | H1, 2020 | H1, 2021 |
|---|---|---|---|
Revenue | 2.6b | 2.7b | 3.1b |
Cost of goods sold | (292.6m) | (303.6m) | (360.3m) |
Gross profit | 2.4b | 2.4b | 2.8b |
R&D expense | (263.9m) | (254.3m) | (344.9m) |
Operating expense total | (1.8b) | (1.4b) | (1.7b) |
Depreciation and amortization | (165.8m) | (174.5m) | (159.7m) |
EBITDA | 619.7m | 1.0b | 1.1b |
EBIT | 417.7m | 820.6m | 946.0m |
Interest expense | (48.2m) | (43.6m) | (32.3m) |
Interest income | 32.9m | 36.8m | 46.1m |
Pre tax profit | 406.6m | 818.6m | 1.0b |
Income tax expense | (95.4m) | (132.8m) | (134.8m) |
Net Income | 311.2m | 685.7m | 891.0m |
3sbio Balance Sheet
Annual
| CNY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Cash | 1.8b | 2.1b | 3.1b | 2.9b |
Accounts Receivable | 1.3b | 930.8m | 860.0m | 1.3b |
Prepaid Expenses | 45.1m | 49.1m | 112.7m | 233.3m |
Inventories | 384.6m | 528.5m | 619.5m | 690.5m |
Current Assets | 4.4b | 4.6b | 6.7b | 7.8b |
PP&E | 1.8b | 2.0b | 2.6b | 3.4b |
Goodwill | 4.1b | 4.1b | 3.9b | 3.8b |
Total Assets | 13.8b | 14.8b | 17.7b | 19.2b |
Accounts Payable | 112.9m | 149.8m | 203.3m | 230.4m |
Short-term debt | 570.3m | 489.4m | 367.2m | 160.8m |
Current Liabilities | 1.7b | 1.6b | 1.5b | 1.4b |
Long-term debt | 2.7b | 2.3b | 2.5b | 2.5b |
Non-Current Liabilities | 3.3b | 2.8b | 3.1b | 3.1b |
Total Debt | 3.3b | 2.8b | 2.9b | 2.6b |
Total Liabilities | 4.9b | 4.4b | 4.6b | 4.6b |
Common Stock | 156.0k | 155.0k | 155.0k | 155.0k |
Additional Paid-in Capital | 4.4b | 4.3b | 4.3b | 4.2b |
Retained Earnings | 3.5b | 4.3b | 5.0b | 6.6b |
Total Equity | 8.9b | 10.4b | 13.1b | 14.7b |
Half Year
| CNY | H1, 2019 | H1, 2020 | H1, 2021 |
|---|---|---|---|
Cash | 1.4b | 3.8b | 2.9b |
Accounts Receivable | 1.5b | 1.1b | 1.2b |
Prepaid Expenses | 756.4m | 504.8m | 582.7m |
Inventories | 449.8m | 569.9m | 681.5m |
Current Assets | 5.1b | 6.9b | 7.4b |
PP&E | 1.8b | 2.1b | 3.0b |
Goodwill | 4.1b | 4.2b | 3.9b |
Total Assets | 14.9b | 17.6b | 18.5b |
Accounts Payable | 170.7m | 166.2m | 214.9m |
Short-term debt | 1.2b | 467.5m | 159.4m |
Current Liabilities | 2.4b | 1.7b | 1.3b |
Long-term debt | 2.4b | 3.9b | 2.5b |
Non-Current Liabilities | 3.0b | 4.5b | 3.1b |
Total Debt | 3.6b | 4.4b | 2.6b |
Total Liabilities | 5.3b | 6.1b | 4.4b |
Common Stock | 155.0k | 155.0k | 156.0k |
Additional Paid-in Capital | 4.3b | 4.3b | 4.3b |
Retained Earnings | 3.7b | 4.9b | 6.0b |
Total Equity | 9.6b | 11.5b | 14.1b |
3sbio Cash Flow
Annual
| CNY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Net Income | 1.5b | 1.2b | 979.1m | 1.9b |
Depreciation and Amortization | 313.3m | 320.7m | 342.1m | 306.4m |
Accounts Receivable | (264.5m) | 453.9m | 34.9m | (401.2m) |
Inventories | (35.7m) | (124.9m) | (93.1m) | (67.1m) |
Accounts Payable | (51.8m) | 37.0m | 53.2m | 27.1m |
Cash From Operating Activities | 1.2b | 1.9b | 1.3b | 1.6b |
Cash From Investing Activities | (405.9m) | (1.1b) | (1.9b) | (1.3b) |
Long-term Borrowings | (1.2b) | (510.5m) | (87.6m) | (93.8m) |
Dividends Paid | (150.8m) | (16.3m) | ||
Cash From Financing Activities | (1.4b) | (454.4m) | 1.6b | (481.1m) |
Net Change in Cash | (606.0m) | 290.2m | 1.0b | (222.8m) |
Half Year
| CNY | H1, 2019 | H1, 2020 | H1, 2021 |
|---|---|---|---|
Net Income | 406.6m | 818.6m | 1.0b |
Depreciation and Amortization | 164.1m | 167.0m | 149.0m |
Accounts Receivable | (75.5m) | (167.5m) | (245.1m) |
Inventories | (66.1m) | (37.3m) | (57.1m) |
Accounts Payable | 57.4m | 16.4m | 11.7m |
Cash From Operating Activities | 699.6m | 708.2m | 811.5m |
Cash From Investing Activities | (1.4b) | (657.5m) | (766.0m) |
Long-term Borrowings | 324.3m | (27.4m) | (197.7m) |
Cash From Financing Activities | 321.9m | 1.6b | (202.9m) |
Net Change in Cash | (412.7m) | 1.7b | (171.2m) |
3sbio Ratios
| CNY | FY, 2018 |
|---|
